We report the case of a late-onset neonatal meningitis by Streptococcus agalactiae (group B Streptococcus - GBS) that was diagnosed with a latex agglutination assay (on cerebrospinal fluid, CSF), as well as by using, for the first time, Xpert GBS (Cepheid, US) on CSF. Due to empirical antibiotics given before sampling, both CSF and blood culture were negative, so the abovementioned diagnostics was crucial. Moreover, the Xpert GBS assay, performed according to an off-label, modified protocol (the system is designed for GBS-carriage intrapartum screening, based on a completely automated real time-Polymerase Chain Reaction) quickly detected the organism's genome target. Although further investigation on this test's performace on CSF is required, then, we trust it may be a promising, quick and precise diagnostic method for infections in newborns.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4152086 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.
Obstet Gynecol
July 2024
Departments of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, and University of South Alabama at Mobile, Mobile, Alabama, University of North Carolina at Chapel Hill, Chapel Hill, and Duke University, Durham, North Carolina, University of Pennsylvania and Drexel University College of Medicine, Philadelphia, and Magee Women's Hospital and University of Pittsburgh, Pittsburgh, Pennsylvania, University of Texas at Houston and the Division of Maternal-Fetal Medicine, Baylor College of Medicine and Texas Children's Hospital, Houston, and University of Texas Medical Branch, Galveston, Texas, Columbia University and Weill Cornell University, New York, and New York Presbyterian Queens Hospital, Flushing, New York, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, Indiana University, Indianapolis, Indiana, University of Utah and Intermountain Healthcare, Salt Lake City, Utah, UnityPoint Health-Meriter Hospital/Marshfield Clinic, Madison, Wisconsin, Washington University in St. Louis, St. Louis, Missouri, University of Mississippi Medical Center, Jackson, Mississippi, The Ohio State University, Columbus, Ohio, Rutgers University-Robert Wood Johnson Medical School, New Brunswick, New Jersey, Medical College of Wisconsin, Milwaukee, Wisconsin, Yale University, New Haven, Connecticut, University of Colorado, Aurora, and Denver Health, Denver, Colorado, Emory University, Atlanta, Georgia.
Objective: To evaluate maternal and neonatal outcomes by type of antihypertensive used in participants of the CHAP (Chronic Hypertension in Pregnancy) trial.
Methods: We conducted a planned secondary analysis of CHAP, an open-label, multicenter, randomized trial of antihypertensive treatment compared with standard care (no treatment unless severe hypertension developed) in pregnant patients with mild chronic hypertension (blood pressure 140-159/90-104 mm Hg before 20 weeks of gestation) and singleton pregnancies. We performed three comparisons based on medications prescribed at enrollment: labetalol compared with standard care, nifedipine compared with standard care, and labetalol compared with nifedipine.
Mean Arterial Pressure and Neonatal Outcomes in Pregnancies Complicated by Mild Chronic Hypertension.
Obstet Gynecol
July 2024
Departments of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, and University of South Alabama at Mobile, Mobile, Alabama, University of North Carolina at Chapel Hill, Chapel Hill, and Duke University, Durham, North Carolina, University of Pennsylvania and Drexel University College of Medicine, Philadelphia, St. Luke's University Health Network, Bethlehem, Magee Women's Hospital and University of Pittsburgh, Pittsburgh, and Lehigh Valley Health Network, Allentown, Pennsylvania, University of Texas at Houston and Baylor College of Medicine and Texas Children's Hospital, Houston, and University of Texas Medical Branch, Galveston, Texas, Columbia University, New York, Winthrop University Hospital, Long Island, and New York Presbyterian Queens Hospital, Flushing, New York, University of Oklahoma, Oklahoma City, Oklahoma, MetroHealth System, Cleveland, The Ohio State University, Columbus, and Wright State University, Fairborn, Ohio, Indiana University, Indianapolis, Indiana, University of Utah Health, Salt Lake City, Utah, Christiana Care Health Services, Newark, Delaware, UnityPoint Health-Meriter Hospital/Marshfield Clinic, Madison, and Medical College of Wisconsin, Milwaukee, Wisconsin, Washington University in St. Louis, St. Louis, Missouri, University of Mississippi Medical Center, Jackson, Mississippi, Yale University, New Haven, Connecticut, University of Colorado, Aurora, and Denver Health Hospital, Denver, Colorado, Emory University, Atlanta, Georgia, University of California, San Francisco, San Francisco, and Stanford University, Stanford, California, Arrowhead Regional Medical Center/Beaumont Hospital, Detroit, Michigan, Virtua Health, Voorhees, New Jersey, Oregon Health & Science University, Portland, Oregon, University of Arkansas for Medical Sciences, Little Rock, Arkansas, University of Tennessee Health Science Center, Memphis, and Vanderbilt University Medical Center, Nashville, Tennessee, Tulane University, New Orleans, Louisiana, University of Kansas Medical Center, Kansas City, Kansas, and Medical University of South Carolina, Charleston, South Carolina; the Center for Women's Reproductive Health, the Department of Biostatistics, and the Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama; Penn State College of Medicine, Hershey, Pennsylvania; Intermountain Health, Salt Lake City, Utah; Ochsner Baptist Medical Center, New Orleans, Louisiana; St. Peters University Hospital and the Department of Obstetrics, Gynecology and Reproductive Health, New Jersey Medical School, Newark, and the Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers University-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Weill Cornell University, New York, New York; Zuckerberg San Francisco General Hospital, San Francisco, California; TriHealth, Cincinnati Children's Hospital, Cincinnati, Ohio; the Division of Cardiovascular Sciences, NHLBI, Bethesda, Maryland; and the Department of Women's Health, University of Texas at Austin, Austin, Texas.
Objective: To estimate the association between mean arterial pressure during pregnancy and neonatal outcomes in participants with chronic hypertension using data from the CHAP (Chronic Hypertension and Pregnancy) trial.
Methods: A secondary analysis of the CHAP trial, an open-label, multicenter randomized trial of antihypertensive treatment in pregnancy, was conducted. The CHAP trial enrolled participants with mild chronic hypertension (blood pressure [BP] 140-159/90-104 mm Hg) and singleton pregnancies less than 23 weeks of gestation, randomizing them to active treatment (maintained on antihypertensive therapy with a goal BP below 140/90 mm Hg) or standard treatment (control; antihypertensives withheld unless BP reached 160 mm Hg systolic BP or higher or 105 mm Hg diastolic BP or higher).
Evaluation of the Xpert Xpress GBS test for rapid detection of group B in pregnant women.
Microbiol Spectr
January 2024
Clinical Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong, China.
This was the first study evaluating the performance of the Xpert Xpress group B (GBS) test using rectovaginal swabs from Chinese pregnant women. Compared to the other three assays, the Xpert Xpress GBS test demonstrated high sensitivity and specificity when screening 939 pregnant women for GBS in rectovaginal specimens. Additionally, its reduced time to obtain results makes it valuable for the rapid detection of GBS.
View Article and Find Full Text PDFGroup B rectovaginal colonization screening on term pregnancies: culture or polymerase chain reaction?
J Matern Fetal Neonatal Med
December 2023
Serviço de Obstetrícia, Unidade Autónoma de Gestão da Mulher e da Criança, Centro Hospitalar Universitário São João, Porto, Portugal.
Objectives: The aim of this study was to evaluate if screening Group B colonization by intrapartum polymerase chain reaction could improve intrapartum administration of antibiotic prophylaxis, compared with antepartum culture screening and analyze the sensitivity and specificity of polymerase chain reaction test.
Methods: 198 pregnant women with Group B colonization antepartum culture screening were included. When they arrived at hospital for delivery, two rectovaginal swabs were collected: for culture and polymerase chain reaction method.
Evaluation of two rapid commercial assays for detection of Streptococcus agalactiae from vaginal samples.
Acta Obstet Gynecol Scand
April 2023
Division of Obstetrics, University Hospital of Zurich, Zurich, Switzerland.
Introduction: Streptococcus agalactiae, also known as group B streptococci (GBS), is associated with invasive infections in neonates. Identification of GBS vaginal colonization in pregnant women before delivery is essential for treatment with antibiotics to prevent intrapartum vertical transmission to the newborn. This study was designed to evaluate applicability of two rapid real-time PCRs in comparison to standard culture identification.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!